Investigators developed chimeric antigen receptors ( CAR s) for expression on T cells more
than 25 years ago. When the CAR is derived from an antibody, the resultant cell should …

Glioblastoma (GBM) is the most aggressive primary brain tumor in adults and is virtually
incurable with conventional therapies. Immunotherapy with T cells expressing GBM-specific …

Purpose The outcome for patients with metastatic or recurrent sarcoma remains poor.
Adoptive therapy with tumor-directed T cells is an attractive therapeutic option but has never …

Purpose: Glioblastoma multiforme (GBM) is the most aggressive human primary brain tumor
and is currently incurable. Immunotherapies have the potential to target GBM stem cells, …

Medulloblastoma is a common malignant brain tumor of childhood. Human epidermal growth
factor receptor 2 (HER2) is expressed by 40% of medulloblastomas and is a risk factor for …

In preclinical models of glioblastoma, antigen escape variants can lead to tumor recurrence
after treatment with CAR T cells that are redirected to single tumor antigens. Given the …

Targeted T cells are emerging as effective non-toxic therapies for cancer. Multiple elements,
however, contribute to the overall pathogenesis of cancer through both distinct and …

Importance Glioblastoma is an incurable tumor, and the therapeutic options for patients are
limited. Objective To determine whether the systemic administration of HER2-specific …

Glioblastoma (GBM) remains incurable with current standard-of-care therapies. Adoptive T
cell transfer holds the promise to improve outcomes for GBM patients. We report on the …

Post-transplant lymphoproliferative disorder (PTLD) is a life-threatening complication after
hematopoietic stem cell or solid organ transplantation. The majority of PTLD is of B-cell origin …